Design, Synthesis, Antimicrobial Evaluation and Molecular Docking Studies of Some Novel Monoterpenoids Substituted Quinoxaline Thiosemicarbazide Derivatives
DOI:
https://doi.org/10.37285/ijpsn.2021.14.2.8Abstract
Owing to the increasingly serious problems caused by multidrug resistance in acquired infection pathogens, it has become an urgent need to develop new classes of antibiotics for overcoming the resistance. The present study aims to increase the antimicrobial activity of quinoxaline thiosemicarbazide derivatives by introducing a hydrophobic alkyl chain, an electron-releasing group in the ring, and substitution by some acyclic, cyclic and bicyclic monoterpenes and their antimicrobial evaluation against various strains with molecular docking studies. The lead molecule (1E, 4E)-1-(7-chloro-3-isopropyl- quinoxalin-2(1H)-ylidene) thiosemicarbazide was synthesized and condensed with various monoterpenes to synthesize different derivatives. The structures of compounds were confirmed through IR., NMR & mass spectroscopy. The synthesized derivatives were evaluated in vitro for antibacterial and antifungal activities against various strains using the agar dilution method. Molecular docking studies of the derivatives (Va– Vg) were performed to find out essential binding sites against target protein (PDB: 3 FAP, receptor: FKBP 12) using Autodock 4.2. The compounds Va, Vd, Vf & Vg exhibited potent antibacterial and antifungal activity. Among all these compounds Vd was found to exhibit more potent activity against gram +Ve, gram –Ve bacterial and fungal strains at MIC 0.19 μg/ml, 0.39μg/ml, and 1.56 μg/ml respectively. The docking studies of all the compounds exhibit potent binding energy, but the compound Vd exhibit interactive binding energy (-9.98 kcal/mol) to the active pockets of the receptor FKBP12. The compound Vd interacting with various active sites of amino acids of receptors like PHE128, TRP190, TYR26, VAL55, ILE56, PHE99, and TRP59. In terms of structure- activity relationship study it is revealed that the activity profile against bacterial and fungal strains was altered by the formation of monoterpenoid substituted (1E, 4E)-1-(7- chloro-3-isopropylquinoxalin-2(1H)-ylidene) thiosemicar- bazide derivatives. The study reveals that bicyclic monoterpenes substituted compounds exhibit greater activity than cyclic and acyclic. The molecular docking studies also showed that all the compounds exhibit good docking energy to bind and inhibit the FKBP12 receptor.
Downloads
Metrics
Keywords:
Monoterpenes, Thiosemicarbazide, Quinoxaline, Antimicrobial, Molecular docking, 3FAP, FKBP12
Downloads
Published
How to Cite
Issue
Section
References
Afrasiabi Z, Sinn E and Padhye S (2003). Transition metal complexes of phenanthrenequinone thiosemicarbazone as potential anticancer agents: synthesis, structure, spectroscopy, electrochemistry and in-vitro anticancer activity against human breast cancer cell-line, T47D. J Inorg Biochem 95(4): 306-314.
Ali MM, Ismail MMF, El-Gaby MSA, Zahran MA and AmmarYA (2000). Synthesis and antimicrobial activities of some novel quinoxalinones derivatives. Molecules 5(6): 864-873.
Badran MM, AbouzidKAM and Hussein MHM (2003). Synthesis of certain substituted Quinoxalines as anti - microbial agents, Part II. ArchPharm Res 26:107–113.
Bharti N, Athar F, Maurya MR and Azam A (2004). Synthesis, characterization and in-vitro anti-amoebic activity of new palladium(II) complexes with 5-nitrothiophene-2-carboxaldehyde N(4)-substituted thiosemicarbazones. Bio Org Med Chem 12(17): 4679–4684.
Carta A, Sanna P, Gherardini L, Usai D and Zanetti S (2001). Novel functionalized pyrido [2,3-9]- quinoxalinones as antibacterial, antifungal and anticancer agents.II Farmaco 56(12): 933– 938.
Chessman GWH and Cookson RF (1979). The Chemistry of Heterocyclic Compounds: Condensed Pyrazines, 1st ed. John Wiley & Sons, United States.
Choi J, Chen J, Schreiber SL and Clardy J (1996).Structures of the FKBP12-rapamycin complex interacting with the binding domain of human FRAP. Science 273(5272): 239-242.
Crowther AF, Curd FHS, Davey DG and Stacey GJ (1949). Synthetic antimalarial, Part XXIX Dialkylaminoalkyl-aminoquinoxalines. J Chem Soc1260–1262.
Cruz MC, Cavallo LM, Gorlach JM, Cox G, Perfect JR, Cardenas ME and Heitman J (1999). Rapamycin antifungal action is mediated via conserved complexes with FKBP12 and TOR kinase homologs in Cryptococcus neoformans. Mol Cell Biol 19(6): 4101- 4112.
Cruz MC, Goldstein AL, Blankenship J, Delpoeta M, Perfect JR, McCusker JH, Bennani YL, Cardenas ME and Heitman J (2001). Rapamycin and less immunosuppressive analogs are toxic to Candida albicans and Cryptococcus neoformans via FKBP12-dependent inhibition of TOR. Antimicrob Agents Chemother 45(11): 3162-3170.
El-Hawash SA, Habib NS and Fanaki NH (1999). Quinoxaline derivatives Part II: Synthesis and antimicrobial testing of 1,2,4- triazolo [4,3- a] quinoxalines, 1,2,4-triazino[4,3-a]- quinoxalines and 2- pyrazolyl quinoxalines. Pharmazie 54(11): 808-815.
European committee for antimicrobial susceptibility testing (EUCAST) of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID). Determination of minimum inhibitory concentrations (MICs) of antibacterial agents by agar dilution. Clinical microbiology and Infection, 2000, 6(9): 509-515. Ganapaty S, Ramalingam P and Rao CB (2007). Antibacterial, antifungal and antitubercular screening of some novel condensed bridgehead nitrogen heterocycles of quinoxalines. Indian J Heterocycl Chem 16(3): 283-286.
Guillon J, Forfar I, Matsuda MM, Desplat V, Saliege M and Thiolat D (2007). Synthesis, analytical behavior and biological evaluation of new 4-substituted pyrrolo [1,2 a] quinoxalines as antileishmanial agents. Bioorg Med Chem Lett 15(1): 194-210.
Hassan SY, Khattab SN, Bekhit AA and Amer A (2006). Synthesis of 3-benzyl-2 substituted quinoxalines as novel monoamine oxidase A inhibitors. Bioorg Med Chem Lett 16(6): 1753-1756.
Hugbo PG (1982). An evolution of antifungal properties of pepper- mint water. International Journal of Pharmaceutics 10: 193-198.
Jaso A, Zarranz B, Aldana I and Monge A (2003). Synthesis of new 2-acetyl and 2-benzoylquinoxaline 1,4-di-N- oxide derivatives as anti-Mycobacterium tuberculosis agents. Eur J Med Chem 38(9):791–800.
Katritzky AR and Rees CW (1984). The structure, reactions, synthesis, and uses of heterocyclic compounds In: Comprehensive Heterocyclic Chemistry Ed.; Pergamon Press: Oxford U.K, 2: 157–97.
Liang J, Choi J and Clardy J (1999). Refined structure of the FKBP12-rapamycin-FRB ternary complex at 2.2 A resolution. Acta Crystallogr D Biol Crystallogr 55(4): 736-744.
Mehul MP, Laxman JP and Sakata G (2014). Design, Synthesis, Molecular Docking, and Antibacterial Evaluation of Some Novel Fluoroquinolone Derivatives as Potent Antibacterial Agent. The Scientific World Journal 8(9): 71-87.
Monge A, Martinez-Crespo FJ, Cerain AL, Palop JA, Narro S, Senador V, Marin A, Sainz Y, Gonzalez M, Hamilton E and Barker AJ (1995). Hypoxia-selective agents derived from 2- quinoxaline carbonitrile 1,2- di-N-oxides 2. J Med Chem 38(22):4488–4494.
Nasr AB, Ponnala D, Sagurthi SR, Kattamuri RK, Marri VK, Gudala S, Lakkaraju C, Bandaru S and Nayarisseri A (2015). Molecular Docking studies of FKBP12-mTOR inhibitors using binding predictions. Bioinformation 11(6): 307–315.
Nasr MNA (2002). Synthesis and antibacterial activity of fused 1,2,4- triazolo[4,3-a] quinoxaline and oxopyrimido [2',1':5,1]- 1,2,4- triazolo[4,3-a] quinoxaline derivatives. Archiv der Pharmazie 335(8): 389-394.
Noorulla S and Sreenivasulu (2011). N Antibacterial activity of novel substituted quinoxaline heterocycles with isoniazide. International Journal of Research in Pharmaceutical and Biomedical Sciences 2(3): 1100-1106.
Obafemi CA and Akinpelu DA (2005). Synthesis and antimicrobial activity of some 2(1H)- Quinoxalinone-6-sulfonyl derivatives. Phosphorus Sulfur Silicon Relat Elem 180(8): 1795-1807.
Plech T, Wujec M, Siwek A, Kosikowska U and Malm A (2011). Synthesis and antimicrobial activity of hiosemicarbazides, s- triazoles and their Mannich bases bearing 3-chlorophenyl moiety. Eur J Med Chem 46(1): 241–248.
Quenelle DC, Keith KA and Kern ER (2006). In-vitro and in-vivo evaluation of isatin-β-thiosemicarbazone and marboran against vaccinia and cowpox virus infections. Antiviral Res 71(1): 24–30. Rangisetty JB, Gupta CNVHB, Prasad AL, Srinivas P, Sridhar N, Parimoo P and Veeranjaneyulu A (2001). Synthesis of new arylaminoquinoxalines and their antimalarial activity in mice. J.Pharmacy and Pharmacology 53(10): 1409–1413.
Refaat HM, Moneer AA and Khalil OM (2004). Synthesis and antimicrobial activity of certain novel quinoxalines. Arch Pharm Res 27:1093-1098.
Ries UJ, Priekpe HW, Havel NH, Handschuh S, Mihm G, Stassen JM, Wienen W and Nar H (2003). Heterocyclic thrombin inhibitors. Part 2: quinoxalinones derivatives as novel, potent antithrombotic agents. Bioorg Med Chem Lett 13: 2297-2302.
Sanna P, Carta A, Loriga M, Zanetti S and Sechi L (1999). Preparation and biological evaluation of 6/7- trifluoromethyl (nitro)-6,7-difluoro-3-alkyl(aryl)-substituted-quinoxalin-2-ones. Part 3. Farmaco 54(3): 169-177.
Sanna P, Carta A, Loriga M, Zanetti S and Sechi L (1999). Synthesis of 3,6,7-substitutedquinoxalin- 2-ones for evaluation of anti- microbial and anticancer activity. Part 2. II, Farmaco 54(3): 161- 168.
Sarges R, Howard HR, Browne RG, Lebel LA, Seymour PA and Koe BK (1990). 4- Amino [1,2,4] triazolo[4,3-a] quinoxalines. A novel class of potent adenosine receptor antagonists and potential rapid-onset antidepressants. J Med Chem 33(8): 2240- 2254.
Sharma S, Athar F, Maurya MR, Naqvi F and Azam A (2005). Novel bidentate complexes of Cu (II) derived from 5-nitrofuran-2- carboxaldehyde thiosemicarbazones with antiamoebic activity against E. histolytica. Eur J Med Chem 40(6): 557–562.
Singh N, Srivastava A, Sodhi A and Ranjan P (2000). In- vitro and in-vivo antitumour studies of a new thiosemicarbazide derivative and its complexes with 3d-metal ions. Trans Met Chem 25:133–40.
Singh S, Bharti N, Naqvi F and Azam A (2004). Synthesis, characterization and in-vitro antiamoebic activity of 5 nitrothiophene-2-carboxaldehyde thiosemicarbazones and their Palladium(II) and Ruthenium(II) complexes. Eur J Med Chem 39(5): 459–65.
Srinivas C, Kumar CNSP, Rao VJ and Palaniappan S (2008). Green approach for the synthesis of quinoxaline derivatives in water medium using reusable polyaniline sulfate salt catalyst and sodium laurylsulfate. Catal Lett 2008, 121(4): 291-296.
Su DS and Bock MG (2005). 2-Quinoxalinone derivatives as bradykinin antagonists and novel Compounds. US Patent Appl 20050020591.
TandonVK, Yadav DB, Maurya HK, Chaturvedi AK and Shukla PK (2006). Design, synthesis and biological evaluation of 1,2,3- trisubstituted-1,4-dihydrobenzo[g] quinoxaline-5,10-diones and
related compounds as antifungal and antibacterial agents.
Bioorg Med Chem 14(17): 6120-6126.
Vasoya S, Paghdar D, Chovatia P and Joshi H (2005). Synthesis of some new thiosemicarbazide and 1,3,4-thiadiazole heterocycles bearing benzo[b]Thiophene nucleus as a potent antitubercular and antimicrobial agents. J Sci Islam Repub Iran. 16(1): 33–36.
Vezina C, Kudelski A and Sehgal SN (1975). Rapamycin (AY- 22,989), a new antifungal antibiotic. I. taxonomy of producing streptomycete and isolation of the active principle. J Antibiot 28(10): 721-726.
Wendt GR and Ledig KW (1969). 6, 7-Dihydroxy-1Hpyrazolo[3,4-6] quinoxaline-5,8-diones.U.S. Patent, 3,431,262, Chem. Abstr.,70, 106512.
Yousef TA, Badria FA, Ghazy SE, El-Gammal OA and Abu El-Reash GM (2011). In-vitro and in-vivo antitumor activity of some synthesized 4-(2-pyridyl)-3-Thiosemicarbazides derivatives. Inter J Med Sci 3(2): 37–46.
Zsuzsanna S, Joseph M and Judit H (2006). Antimicrobial and antiplasmid activities of essential oils. Fitoerapia. 77(4): 279- 285.
